Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice

Vaccine

Volumn 30, Issue 27, 2012, Pages 4040-4045

  Arama, Charles ^a   Assefaw Redda, Yohannes ^a   Rodriguez, Ariane ^b   Fernández, Carmen ^a   Corradin, Giampietro ^c   Kaufmann, Stefan H E ^d   Reece, Stephen T ^d   Troye Blomberg, Marita ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b CRUCELL HOLLAND BV   (Netherlands)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Ad35 CS; BCG CS; Heterologous prime boost; Long lived plasma cells; Malaria vaccines; Plasmodium falciparum circumsporozoite protein

Indexed keywords

ADENOVECTOR 35 CIRCUMSPOROZOITE PROTEIN VACCINE; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MALARIA VACCINE; RECOMBINANT BACILLUS CALMETTE GUERIN CIRCUMSPOROZOITE PROTEIN VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; LONG TERM MEMORY; MOUSE; NONHUMAN; PLASMA CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, PROTOZOAN; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; TH1 CELLS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84861480702     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.029     Document Type: Article

References (36)

1. Friesen J., Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011, 29(40):7002-7008.
2. Slifka M.K., Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Current Opinion in Immunology 1998, 10(3):252-258.
3. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Human Vaccines 2010, 6(1).
4. Kappe S.H., Vaughan A.M., Boddey J.A., Cowman A.F. That was then but this is now: malaria research in the time of an eradication agenda. Science 2010, 328(5980):862-866.
5. Greenwood B. Immunological correlates of protection for the RTS,S candidate malaria vaccine. Lancet Infectious Diseases 2011, 11(2):75-76.
6. Arama C., Waseem S., Fernandez C., Assefaw-Redda Y., You L., Rodriguez A., et al. A recombinant Bacille Calmette-Guerin construct expressing the Plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine 2011.
7. Ferraz J.C., Stavropoulos E., Yang M., Coade S., Espitia C., Lowrie D.B., et al. A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70: Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infection and Immunity 2004, 72(12):6945-6950.
8. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24(21):4554-4561.
9. Vordermeier H.M., Villarreal-Ramos B., Cockle P.J., McAulay M., Rhodes S.G., Thacker T., et al. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infection and Immunity 2009, 77(8):3364-3373.
10. Schmidt N.W., Podyminogin R.L., Butler N.S., Badovinac V.P., Tucker B.J., Bahjat K.S., et al. Memory CD8T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(37):14017-14022.
11. Ophorst O.J., Radosevic K., Havenga M.J., Pau M.G., Holterman L., Berkhout B., et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infection and Immunity 2006, 74(1):313-320.
12. Radosevic K., Rodriguez A., Lemckert A.A., van der Meer M., Gillissen G., Warnar C., et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clinical and Vaccine Immunology 2010, 17(11):1687-1694.
13. Overstreet M.G., Cockburn I.A., Chen Y.C., Zavala F. Protective CD8T cells against Plasmodium liver stages: immunobiology of an 'unnatural' immune response. Immunological Reviews 2008, 225:272-283.
14. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2-a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29(17):3284-3292.
15. Amanna I.J., Carlson N.E., Slifka M.K. Duration of humoral immunity to common viral and vaccine antigens. New England Journal of Medicine 2007, 357(19):1903-1915.
16. Manz R.A., Arce S., Cassese G., Hauser A.E., Hiepe F., Radbruch A. Humoral immunity and long-lived plasma cells. Current Opinion in Immunology 2002, 14(4):517-521.
17. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunological Reviews 2010, 236:125-138.
18. Radosevic K., Rodriguez A., Lemckert A., Goudsmit J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Review of Vaccines 2009, 8(5):577-592.
19. Blum-Tirouvanziam U., Beghdadi-Rais C., Roggero M.A., Valmori D., Bertholet S., Bron C., et al. Elicitation of specific cytotoxic T cells by immunization with malaria soluble synthetic polypeptides. Journal of Immunology 1994, 153(9):4134-4141.
20. Roggero M.A., Filippi B., Church P., Hoffman S.L., Blum-Tirouvanziam U., Lopez J.A., et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Molecular Immunology 1995, 32(17-18):1301-1309.
21. Anderson R.J., Hannan C.M., Gilbert S.C., Laidlaw S.M., Sheu E.G., Korten S., et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. Journal of Immunology 2004, 172(5):3094-3100.
22. Reyes-Sandoval A., Berthoud T., Alder N., Siani L., Gilbert S.C., Nicosia A., et al. Prime-boost immunization with adenoviral and modified vaccinia virus ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infection and Immunity 2010, 78(1):145-153.
23. Reyes-Sandoval A., Wyllie D.H., Bauza K., Milicic A., Forbes E.K., Rollier C.S., et al. CD8+ T effector memory cells protect against liver-stage malaria. Journal of Immunology 2011, 187(3):1347-1357.
24. Nojima T., Haniuda K., Moutai T., Matsudaira M., Mizokawa S., Shiratori I., et al. In vitro derived germinal centre B cells differentially generate memory B or plasma cells in vivo. Nature Communications 2011, 2:465.
25. Olotu A., Moris P., Mwacharo J., Vekemans J., Kimani D., Janssens M., et al. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01(E) and protection against P. falciparum clinical malaria. PLoS One 2011, 6(10):e25786.
26. Limbach K.J., Richie T.L. Viral vectors in malaria vaccine development. Parasite Immunology 2009, 31(9):501-519.
27. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., Guillet J.G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. European Journal of Immunology 1995, 25(12):3467-3473.
28. Mukai T., Maeda Y., Tamura T., Matsuoka M., Tsukamoto Y., Makino M. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein. Journal of Immunology 2009, 183(10):6561-6568.
29. Stewart V.A., McGrath S.M., Dubois P.M., Pau M.G., Mettens P., Shott J., et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and Immunity 2007, 75(5):2283-2290.
30. de Cassan S.C., Forbes E.K., Douglas A.D., Milicic A., Singh B., Gupta P., et al. The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. Journal of Immunology 2011, 187(5):2602-2616.
31. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. Journal of Infectious Diseases 2012, 205(5):772-781.
32. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. Journal of Leukocyte Biology 2004, 75(2):163-189.
33. Chizzolini C., Grau G.E., Geinoz A., Schrijvers D. T lymphocyte interferon-gamma production induced by Plasmodium falciparum antigen is high in recently infected non-immune and low in immune subjects. Clinical and Experimental Immunology 1990, 79(1):95-99.
34. Luty A.J., Lell B., Schmidt-Ott R., Lehman L.G., Luckner D., Greve B., et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. Journal of Infectious Diseases 1999, 179(4):980-988.
35. Rozanski C.H., Arens R., Carlson L.M., Nair J., Boise L.H., Chanan-Khan A.A., et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. Journal of Experimental Medicine 2011, 208(7):1435-1446.
36. Weiss G.E., Traore B., Kayentao K., Ongoiba A., Doumbo S., Doumtabe D., et al. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathogens 2010, 6(5):e1000912.